Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Curr Cancer Drug Targets. 2018;18(2):109-123. doi: 10.2174/1568009617666170206111609.
Oncolytic viruses are a promising anti-cancer platform, achieving significant pre-clinical and clinical milestones in recent years. A full arsenal of selective, safe, and effective viruses has been developed with some emerging pre-clinical research focusing on optimizing these therapies in the face of remaining challenges, both in the bloodstream and in the tumour microenvironment. Herein we discuss the recent progress in pre-clinical virotherapy research to address these challenges, with special focus on innovative strategies that seek to complement the current strengths of virotherapy, ensuring an optimal multi-faceted attack on cancer. This review highlights the research areas that we believe provide the most potential to increase the efficacy of this exciting biotherapy platform: cell carriers, tumour vascular destruction, microenvironment modulation, combination therapies, and virus-mediated anti-tumour immune responses.
溶瘤病毒是一种很有前途的抗癌平台，近年来在临床前和临床方面取得了重大进展。已经开发出了一整套具有选择性、安全性和有效性的病毒，一些新兴的临床前研究专注于优化这些疗法，以应对在血液和肿瘤微环境中仍然存在的挑战。本文讨论了临床前病毒疗法研究的最新进展，以解决这些挑战，特别关注旨在补充病毒疗法现有优势的创新策略，确保对癌症进行最佳的多方面攻击。本综述强调了我们认为最有潜力提高这一令人兴奋的生物治疗平台疗效的研究领域：细胞载体、肿瘤血管破坏、微环境调节、联合治疗和病毒介导的抗肿瘤免疫反应。
